Entries by Dan Zapata

La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress

La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress SAN DIEGO, May 10, 2018 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced financial results for […]

GIAPREZA™ (angiotensin II) Significantly Improved Survival and Reduced Time on Renal Replacement Therapy in Patients with Acute Kidney Injury

Analyses to Be Presented in Oral and Poster Sessions at The 23rd International Conference on Advances in Critical Care Nephrology AKI & CRRT 2018 Manuscript Published Online in Critical Care Medicine SAN DIEGO, March 06, 2018 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq:LJPC) today announced the release of data from analyses of the impact […]

GIAPREZA™ (angiotensin II) Significantly Improved Survival of Patients with High APACHE II Scores in ATHOS-3 Study

Analysis to Be Presented in Oral Session at the Society of Critical Care Medicine’s 47th Critical Care CongressSAN DIEGO, Feb. 25, 2018 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq:LJPC) today announced that an abstract, entitled “Effect of Disease Severity on Survival in Patients Receiving Angiotensin II for Vasodilatory Shock,” will be presented at the Society of Critical Care Medicine’s […]

La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress

SAN DIEGO, Calif., Feb. 22, 2018 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq:LJPC), a leader in the development of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announced financial results for the three and twelve months ended December 31, 2017 and highlighted recent corporate progress. Recent Corporate Progress In December 2017, GIAPREZA™ (angiotensin II), injection for […]

La Jolla Pharmaceutical Company Announces the Treatment of First Patient in GIAPREZA™ (angiotensin II) Pediatric Study

SAN DIEGO, Feb. 21, 2018 (GLOBE NEWSWIRE) — La Jolla Pharmaceutical Company (Nasdaq:LJPC) today announced that the first pediatric patient has been treated in LJ501-CRH02, La Jolla’s open-label study of GIAPREZATM (angiotensin II), injection for intravenous infusion, in pediatric patients (ages 2-17) with shock who remain hypotensive despite receiving fluid and current standard-of-care vasopressor therapy. LJ501-CRH02 is an open-label study […]

La Jolla Pharmaceutical Company Announces Initiation of Multicenter, Randomized, Phase 2 Clinical Study of LJPC-401 in Patients with Hereditary Hemochromatosis

SAN DIEGO, CA – December 18, 2017 – La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla) today announced the initiation of LJ401-HH01, a Phase 2 clinical study of LJPC-401 (synthetic human hepcidin) in patients with hereditary hemochromatosis (HH). The most common genetic disease in Caucasians, HH is a disease characterized by a […]

La Jolla Pharmaceutical Company Announces Initiation of Pivotal Clinical Study of LJPC-401 in Patients with Beta Thalassemia

SAN DIEGO, CA – December 4, 2017 – La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla) today announced the initiation of a pivotal clinical study of LJPC-401 (synthetic human hepcidin) in patients with transfusion-dependent beta thalassemia who, despite chelation therapy, have cardiac iron levels above normal. A high level of cardiac iron […]